Thymic Carcinoma clinical trials

Explore recruiting thymic carcinoma clinical trials.

Recruiting thymic carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Thymic Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

“A Multicentric, Open-Label, Single Arm Phase II Study To Evaluate The Efficacy And Safety Of The Combination Of PEmbrolizumab And Lenvatinib In Pre-Treated Thymic CArcinoma PaTIents. PECATI”.

Spain, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

EORTC-1525-LCG: Single-arm, multicenter, phase II study of immunotherapy in patients with type B3 thymoma and thymic carcinoma previously treated with chemotherapy - (Nivothym)

Belgium, Spain, Netherlands, France

Therapeutic exploratory (Phase II) EU CTIS Study details

IMMUNORARE5 : A national platform of 5 academic phase II trials coordinated by Lyon university hospital to assess the safety and the efficacy of the IMMUNOtherapy with Domvanalimab + Zimberelimab combination in patients with advanced RARE cancers

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced cancers

Italy, Spain, France, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Thymic Carcinoma trials by city

Thymic Carcinoma in Toronto Thymic Carcinoma in Vancouver Thymic Carcinoma in Montreal Thymic Carcinoma in Calgary Thymic Carcinoma in Edmonton Thymic Carcinoma in Ottawa Thymic Carcinoma in Winnipeg Thymic Carcinoma in Quebec City Thymic Carcinoma in Hamilton Thymic Carcinoma in Kitchener Thymic Carcinoma in London Thymic Carcinoma in Halifax Thymic Carcinoma in New York Thymic Carcinoma in Los Angeles Thymic Carcinoma in Chicago Thymic Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease